Atlas Principals’s Guardant Health GH Stock Holding History

Atlas Principals’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-17,500	Closed	-$1.96M	–	38
2020 Q3	$1.96M	Buy	+17,500	New	+$1.6M	0.98%	26

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Atlas Principals's GH Position: Q4 2020 in Review

Atlas Principals sold out of Guardant Health (GH) in Q4 2020, closing a stake of 17,500 shares — an estimated $1.96M sold.

Atlas Principals first reported a position in GH in Q3 2020 and held it in 1 quarter. The position peaked at $1.96M in Q3 2020. 419 funds tracked by Wall St. Rank hold GH as of Q4 2020.

Atlas Principals reported no remaining Guardant Health position as of Q4 2020 after selling out during the quarter.
Atlas Principals sold 17,500 Guardant Health shares in Q4 2020, an estimated $1.96M.
Atlas Principals first reported a position in Guardant Health in Q3 2020 and held it in 1 quarter.
Atlas Principals's Guardant Health position peaked at $1.96M in Q3 2020.
419 funds tracked by Wall St. Rank held Guardant Health as of Q4 2020.

Based on Atlas Principals's 13F filing for Q4 2020, filed 16 Feb 2021.